Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)504.86m
- Net income in EUR19.37m
- Incorporated1967
- Employees2.74k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang Cheng Yi Pharmaceutical Co Ltd | 98.68m | 28.24m | 456.60m | 738.00 | 15.98 | 2.77 | -- | 4.63 | 0.6997 | 0.6997 | 2.46 | 4.04 | 0.4508 | 1.95 | 20.88 | -- | 13.02 | 11.48 | 15.87 | 14.03 | 68.99 | 69.02 | 28.88 | 24.63 | 0.985 | -- | 0.0808 | 37.22 | 6.36 | 0.9546 | 23.21 | 8.84 | -20.09 | 11.39 |
| Shanghai Shen Lian Biomedical Corp | 36.54m | -3.79m | 457.06m | 391.00 | -- | 2.60 | -- | 12.51 | -0.0739 | -0.0739 | 0.713 | 3.43 | 0.1864 | 1.42 | 0.9144 | 748,865.90 | -2.21 | 3.53 | -2.40 | 3.80 | 57.36 | 73.49 | -11.87 | 16.93 | 3.64 | -- | 0.0106 | 43.52 | 0.6394 | 3.63 | -241.95 | -- | -3.99 | -- |
| CorMedix Inc | 184.51m | 139.91m | 468.75m | 64.00 | 3.37 | 1.45 | 3.26 | 2.54 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Boiron SA | 504.86m | 19.37m | 471.97m | 2.74k | 24.11 | 1.27 | 7.69 | 0.9349 | 1.12 | 1.12 | 29.08 | 21.26 | 0.9021 | 1.30 | 6.51 | 182,193.40 | 3.46 | 4.01 | 4.34 | 5.04 | 73.71 | 73.23 | 3.84 | 5.81 | 1.46 | -- | 0.0467 | 66.42 | -1.15 | -2.63 | -68.36 | -22.53 | -15.75 | 2.71 |
| Shanghai MicuRx Pharmaceutical Co Ltd | 17.06m | -42.79m | 474.92m | 188.00 | -- | 14.76 | -- | 27.84 | -0.5197 | -0.5197 | 0.2077 | 0.3929 | 0.161 | 0.4661 | 3.95 | 727,105.00 | -40.40 | -31.40 | -53.04 | -35.41 | 84.26 | 82.42 | -250.89 | -503.67 | 2.15 | -406.30 | 0.5862 | -- | 43.51 | -- | -4.65 | -- | 51.72 | -- |
| Supriya Lifescience Ltd | 68.79m | 17.33m | 478.48m | 515.00 | 27.58 | -- | 24.21 | 6.96 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| Shandong Boan Biotechnology Co Ltd | 94.87m | 4.02m | 486.75m | 714.00 | 111.03 | 1.76 | 33.33 | 5.13 | 0.0639 | 0.0639 | 1.51 | 4.02 | 0.2530 | 1.34 | 1.73 | 1,057,833.00 | 1.07 | -- | 1.41 | -- | 71.70 | -- | 4.23 | -- | 1.45 | 1.81 | 0.2827 | -- | 17.50 | -- | 161.31 | -- | -- | -- |
| VIVA Biotech Holdings | 230.26m | 21.60m | 491.06m | 2.09k | 29.38 | 0.9967 | 8.82 | 2.13 | 0.0711 | 0.0711 | 0.6839 | 2.10 | 0.2612 | 4.24 | 4.94 | 1,011,754.00 | 3.22 | -1.28 | 3.81 | -1.56 | 37.44 | 34.30 | 12.33 | -4.94 | 1.44 | -- | 0.2283 | -- | -7.84 | 43.80 | 244.08 | -8.85 | 27.82 | -- |
Data as of Mar 04 2026. Currency figures normalised to Boiron SA's reporting currency: Euro EUR
5.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2025 | 182.45k | 1.04% |
| Financi�re de l'�chiquier SAas of 30 Sep 2025 | 134.96k | 0.77% |
| Gay-Lussac Gestion SAas of 31 Dec 2024 | 106.00k | 0.60% |
| HMG Finance SAas of 31 Dec 2025 | 100.05k | 0.57% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 89.26k | 0.51% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 78.53k | 0.45% |
| DNCA Finance SAas of 31 Mar 2025 | 75.05k | 0.43% |
| Amiral Gestion SAas of 30 Jun 2025 | 62.05k | 0.35% |
| Sycomore Asset Management SAas of 30 Jan 2026 | 30.12k | 0.17% |
| Chaussier Gestion SAas of 31 Dec 2025 | 19.00k | 0.11% |
More ▼
Data from 31 Dec 2024 - 31 Jan 2026Source: FactSet Research Systems Inc.
